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Background: Despite the widespread recognition that obesity in pregnant women is associated with adverse
outcomes for mother and child, there is no intervention proven to reduce the risk of these complications. The
primary aim of this randomised controlled trial is to assess in obese pregnant women, whether a complex
behavioural intervention, based on changing diet (to foods with a lower glycemic index) and physical activity, will
reduce the risk of gestational diabetes (GDM) and delivery of a large for gestational age (LGA) infant. A secondary
aim is to determine whether the intervention lowers the long term risk of obesity in the offspring.
Methods/Design: Multicentre randomised controlled trial comparing a behavioural intervention designed to
improve glycemic control with standard antenatal care in obese pregnant women.
Inclusion criteria; women with a BMI ≥30 kg/m2 and a singleton pregnancy between 15+0 weeks and 18+6 weeks’
gestation. Exclusion criteria; pre-defined, pre-existing diseases and multiple pregnancy. Randomisation is on-line by
a computer generated programme and is minimised by BMI category, maternal age, ethnicity, parity and centre.
Intervention; this is delivered by a health trainer over 8 sessions. Based on control theory, with elements of social
cognitive theory, the intervention is designed to improve maternal glycemic control. Women randomised to the
control arm receive standard antenatal care until delivery according to local guidelines. All women have a 75 g oral
glucose tolerance test at 27+0- 28+6 weeks’ gestation.
Primary outcome; Maternal: diagnosis of GDM, according to the International Association of Diabetes in Pregnancy
Study Group (IADPSG) criteria. Neonatal; infant LGA defined as >90th customised birth weight centile.
Sample size; 1546 women to provide 80% power to detect a 25% reduction in the incidence of GDM and a 30%
reduction in infants large for gestational age.
Discussion: All aspects of this protocol have been evaluated in a pilot randomised controlled trial, with subsequent
optimisation of the intervention. The findings of this trial will inform whether lifestyle mediated improvement of
glycemic control in obese pregnant women can minimise the risk of pregnancy complications.
Trial registration: Current controlled trials; ISRCTN89971375.
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The rise in the global incidence of obesity has reached
pandemic proportions [1]. In 2008, the World Health
Organisation (WHO) estimated there were 1.5 billion indi-
viduals with a body mass index (BMI) ≥ 25 kg/m2 including
nearly 300 million obese women (BMI ≥ 30 kg/m2) [2].
The United Kingdom (UK) has seen a sharp increase in
the proportion of obese women; as reported in a recent
survey, approximately one in five women aged between
16 and 44 are obese [3]. The UK Confidential Enquiry
into Maternal and Child Health identified that over-
weight and obesity, was either directly or indirectly the
cause of over half of maternal mortality [4]. The adverse
effects of obesity on reproductive health and childbearing
are manifold. Obesity reduces fertility, and in pregnancy is
associated with a heightened risk of gestational diabetes
mellitus (GDM), hypertensive disorders of pregnancy in-
cluding pre-eclampsia, and failure to progress in labour.
Caesarean section rates are high, and infants of obese
mothers are at greater risk of congenital malformation,
large for gestational age at delivery (LGA) (>90th centile),
macrosomia, shoulder dystocia and stillbirth. Following
delivery, obese women are more likely to suffer a postpar-
tum haemorrhage, and have longer hospital stays than
women with a normal BMI (18.5-24.9 kg/m2) [5,6]. The
effects of obesity may extend beyond health in pregnancy;
increasing evidence suggests that the children of obese
women or of those whose gestational weight gain (GWG)
was excessive, may be at greater risk of obesity because of
antenatal exposure to adverse metabolic influences in
utero, or in the early postnatal period [7,8].
In the UK, in contrast to the United States (US), women
are no longer routinely weighed in pregnancy, except at
their first antenatal appointment. The US Institute of
Medicine (IOM) guidelines for weight gain during preg-
nancy provide recommendations for women according
to their pre-pregnancy BMI, recommending that obese
women should gain less weight in pregnancy (11-20 lb;
5-9 kg) than those with a lower pre-pregnancy BMI [9].
This advice is based on observational studies suggesting
improved outcomes with lower weight gain. The UK
National Institute for Health and Clinical Excellence
(NICE) guidelines on weight management in pregnancy
concluded that more evidence of improved outcomes
from interventional studies is required before the US or
similar guidelines for limitation of GWG are adopted
[10]. Whilst review of the literature suggests that interven-
tion studies designed to limit GWG may sometimes be
effective in achieving a reduction in GWG, there is at
present, no evidence for improvement of pregnancy out-
come amongst obese women. However most studies, in-
cluding those in overweight and obese pregnant women,
have been small, not powered for clinical outcomes and
have had limitations in the design [11,12].The role of insulin resistance in obese pregnancies
An alternative approach to restricting GWG is to focus
on the adverse clinical outcomes associated with obesity,
and to develop interventions which are directly associated
with known underlying mechanisms. A pre-pregnancy
BMI ≥30 kg/m2 irrespective of the amount of weight
gained during pregnancy, is the most important inde-
pendent determinant of the risk of caesarean section,
delivery of a LGA infant and postpartum weight reten-
tion [13]. Also, the evidence linking GWG with GDM,
in contrast to the strong association with pre-pregnancy
BMI, is relatively weak [14]. This is, at least in part,
likely to be a reflection of the strong association be-
tween maternal fat mass and insulin resistance [7].
There is a physiological increase in insulin resistance
during normal pregnancy and the obese pregnant
woman is at greater risk of developing GDM. Maternal
hyperglycemia and, more recently, maternal hypertri-
glyceridemia are strongly implicated in the development
of fetal macrosomia [15-18]. Using the method of continu-
ous blood glucose monitoring, Harmon et al. have shown,
as might be anticipated, that obese pregnant women have
an exaggerated post prandial glucose response [17]. As
the magnitude of the post prandial response was directly
implicated in increasing fetal adiposity and birth weight
through fetal hyperinsulinemia, a dietary intervention
focusing on reducing post prandial hyperglycemia by low-
ering the dietary glycemic load could improve maternal
glucose control, reduce the incidence of GDM and lower
the incidence of LGA infants. Similarly, pre-eclampsia is
associated with maternal insulin resistance, and improved
glucose homeostasis might lower the risk of pre-eclampsia
in obese women [19].
Improving glycemic control in pregnancy
Specific dietary advice and increased physical activity
could contribute to improved maternal glucose homeosta-
sis [20]. In a study of 50 obese Danish women designed to
limit GWG, Wolff et al. [21] found that an intense dietary
regime (10 one-hour sessions with a dietician) focusing on
healthy eating, resulted in a reduction of plasma insulin
compared to women in the control arm of the study.
Another study reported that a diet and exercise regime led
to a reduction in GWG and a decrease in the incidence
of GDM in 126 overweight and obese Australian women
[22], but no difference in birth weight (3.5 kg versus
3.4 kg). In non-obese women with mild GDM, in whom
improved glucose homeostasis is achieved through a strict
regime of dietary intervention and insulin treatment when
required, a reduction in the risk of adverse pregnancy out-
come is achievable, as shown in two randomised con-
trolled trials [23,24]. Higher levels of physical activity in
normoglycemic pregnant women and those with GDM
have also been shown to improve insulin sensitivity [7], but
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pregnant population. A recent meta-analysis of eight pre-
natal physical activity intervention studies however, showed
that there was a lack of consistent evidence regarding the
benefits of exercise combined or not combined with dietary
advice for improving glucose tolerance in obese pregnant
women, which was interpreted to reflect the limited power
of current evidence and poor intervention compliance [25].
Systematic review of the literature
Louie et al. conducted a systematic review of the influ-
ence of lowering dietary glycemic index (GI) in pregnan-
cies across all BMI categories [26]. Of the eight studies
included, two suggested that a low GI diet can reduce
the risk of LGA infants in healthy pregnancies, but one
reported an increase in small for gestational age (SGA)
infants. In the three studies in which pregnancies were
complicated by GDM the evidence supported the overall
advantages of a low GI diet. This review recommended
that until larger scale intervention trials are completed,
a low GI diet should not replace the current dietary rec-
ommendations from government and health agencies,
and that further research regarding the optimal time to
start a low GI diet for maximum protection against
adverse pregnancy outcomes is warranted.
In a systematic review of nine randomised trials includ-
ing 743 overweight and obese pregnant women, Dodd
et al. reported that there was no significant effect of in-
terventions designed to limit GWG on weight gain or on
delivery of a LGA infant [11]. In a later systematic review
of thirteen randomised clinical trials of lifestyle interven-
tions in overweight and obese pregnant women (n = 1228)
we concluded that there was a modest influence on
GWG (-2.21 kg; 95% confidence interval (CI) -2.86 kg
to -1.59 kg), but no significant effect on any relevant
clinical outcome [27]. We have also reviewed dietary and
physical activity interventions in normal BMI and obese
pregnant women (n = 1656 women) for the purpose of
limiting GWG; in a systematic review we assessed 12 tri-
als. Overall, diet and physical activity change was effective
in reducing GWG, but there was considerable heterogen-
eity in outcomes [28]. The analysis highlighted differences
in sample characteristics and aspects of intervention de-
sign, content, delivery and evaluation which might explain
variation in effectiveness. Furthermore, failure to evaluate
changes in behaviour or its psychological determinants
could have obscured identification of the processes by
which weight change is effective, and limited the ability to
discern active intervention ingredients. We concluded that
interventions should be more systematically designed and
built on insights from behavioural science.
More recently, Thangaratinam et al., in a meta-analysis
evaluated 44 clinical trials using lifestyle or dietary inter-
ventions or a combination of both during pregnancyacross all BMI ranges, found a reduction in GWG (1.42 kg
reduction) with any intervention in comparison to the
control [12]. Physical activity alone, was associated with a
reduction in birth weight (mean difference -60 g, 95% CI
-120 g to -10 g). Interventions based on diet were the
most effective, being associated with reductions in mater-
nal GWG (3.84 kg, 95% CI 2.45 to 5.22 kg) and a modest
improvement of obstetric outcomes. However, the com-
bination of intervention methods did not result in a re-
duction in the incidence of LGA between the groups (RR
0.85, 95% CI 0.66 to 1.09). Amongst obese women, there
was no evidence for an improvement of any clinical out-
come. In an editorial, to this review, we highlighted that
there remains a paucity of information regarding intensity,
duration and compliance of the interventions, all of which
could account for the lack of efficacy, as well minimal evi-
dence for any effect of the intervention on the targeted be-
haviours. If the intervention does not achieve a change of
behaviour in the anticipated direction, it follows that there
will be no influence on clinical outcomes [29].
The protocol presented here describes a complex be-
havioural intervention comprising dietary and physical
activity changes which we have developed with the aim
of improving glycemic control in obese pregnant
women. The intervention is based on established con-
trol theory with elements of social cognitive theory
[30,31]. The primary hypothesis being tested is that an
antenatal intervention package of low glycemic dietary
advice combined with advice on increased physical ac-
tivity will reduce the incidence of maternal GDM and
LGA infants. A secondary hypothesis is that the inter-
vention will reduce the risk of obesity in the child. Prior
to undertaking a trial adequately powered to investigate
clinical outcomes, we completed a pilot study (n = 183
women) to determine whether the intervention changed
dietary and physical behaviours as anticipated [32]. This
pilot study showed that diet but not physical activity
(as objectively measured) changed with the intervention
and that all aspects of the protocol were feasible. A
process evaluation led to optimisation of intervention de-
livery. The trial steering committee recommended con-
tinuation with recruitment for the randomised controlled
trial (RCT), and it was decided that the physical activity
aspect of the intervention should remain, as this follows
standard guidelines for pregnant women [33].
Methods/Design
Study design
Multicentre RCT. For participating centres see the UP-
BEAT trial website: http://www.medscinet.net/upbeat/.
Ethical approval
NHS Research Ethics Committee approval was obtained
in all centres (UK IRAS integrated research application
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with a singleton pregnancy, 15+0- 18+6 weeks’ gestation and
body mass index ≥30 kg/m2 at first antenatal appointment.
Exclusion criteria
Women unable or unwilling to give informed consent;
<15+0 weeks or >18+6 weeks’ gestation; essential hyper-
tension requiring treatment either pre-pregnancy or in
index pregnancy; pre-existing renal disease; systemic
lupus erythematosus; antiphospholipid syndrome; sickle
cell disease; thalassemia; coeliac disease; thyroid disease;
current psychosis; multiple pregnancy; currently pre-
scribed metformin.
The protocol for the study is shown in Figure 1.
Trial entry
Eligible women are identified in antenatal clinics and
from general practitioner and midwives referral letters.
Verbal and written information is given. Research mid-
wives contact potential recruits, obtain verbal consent
and arrange the first appointment. For those who decline
to participate, permission is sought to collect minimal
pregnancy outcome data.
15+0-18+6 weeks’ appointment: baseline and randomisation
At the first appointment, written informed consent is ob-
tained. Baseline demography, medical and family history
and current pregnancy information is collected. A short
validated food frequency questionnaire (FFQ) [34] is com-
pleted to evaluate dietary glycemic load, dietary glycemic
index, saturated fat and total sugar intake and other diet-
ary variables. Women are weighed, pulse and blood pres-
sure are checked, anthropometric measurements obtained
and blood and urine samples taken. Behavioural and psy-
chological measures include; the EuroQuol Quality of life
(EQ-5D) [35], the Edinburgh Postnatal Depression Scale
(EPDS) [36], the International Physical Activity Question-
naire (IPAQ) [37], and a ‘binge eating’ screening question-
naire [38]. Randomisation occurs at this visit via a secure
internet based data management system (MedSciNet™),
which is the repository for all trial data. The randomi-
sation schedule is minimised according to ethnicity,
parity (0 versus ≥ 1), age, BMI (BMI 30-34.9 kg/m2 ver-
sus 35-39.9 kg/m2 and >40 kg/m2) and centre. Rando-
mised women are allocated sequential study numbers,
regardless of allocation to the intervention or standard
care group.
Intervention
Women randomised to the intervention group attend a
one-to-one interview with the health trainer, which in-
cludes discussion of the potential benefits of attending the
weekly sessions. In the UK, health trainers help people to
change their behaviour to achieve personal choices andgoals, and generally do not have pre-specified health pro-
fessional qualifications, but relevant experience. All health
trainers in this trial receive study-specific training in all
aspects of the intervention and ongoing support through-
out the trial. Women in the intervention group receive a
participant handbook, a DVD of an exercise regime safe
for pregnancy, a pedometer and a logbook for recording
weekly SMART (Specific, Measurable, Achievable, Rele-
vant and Time specific) goals, and steps as assessed by
pedometer. They are invited to attend 8 sessions with the
health trainer on a weekly basis, each lasting 1 to 1.5 hours.
Women are encouraged to attend all sessions, but are
strongly recommended to attend a minimum of five.
For the sessions not attended in person, the health
trainer covers the session material by phone or email.
Attendance and coverage of session material are do-
cumented in the study database. Following a review of
the dietary and physical intervention, each session is de-
signed to focus on different approaches in achieving the
goals set. These include SMART goals, self monitoring,
and provision of feedback regarding goal attainment,
identification and problem solving of barriers, enlisting
social support and providing opportunities for social
comparison. At each session, review of the previous
weeks’ goals is undertaken.
The dietary intervention aims to promote a healthier
pattern of eating, similar to that used in diabetes preven-
tion studies, but does not aim to restrict energy intake. In
order to decrease the glycemic load, dietary advice in-
cludes exchanging starchy foods with a medium/high GI
for those with a lower dietary GI, and restricting the con-
sumption of sugar-sweetened beverages (including fruit
juice) but not fruit. Participants are also given dietary
advice to reduce saturated fatty acid intake.
Advice regarding physical activity focuses on increas-
ing the daily step count incrementally, and being more
active in daily life. Pedometers are used for monitoring
and motivation. The emphasis is on walking at a mod-
erate intensity with additional options included, espe-
cially for those who are already engaging in some
physical activity. This degree of activity accords with
that recommended by the UK Royal College of Obste-
tricians and Gynaecologists [33].
Standard care
Women randomised to the standard care group attend
routine antenatal care according to local health care
provision. UK recommendations state that women with a
BMI ≥ 30 kg/m2 should be advised by a health professional
at the earliest opportunity of the risks of obesity in preg-
nancy and be given advice about a healthy diet and safe
levels of physical activity. Recommendations for referral
to a registered dietician are infrequently implemented.
Women are only weighed at their first antenatal visit [10].
Session – week 4 
14 weeks’ gestation: Research midwife approaches eligible women-verbal 
and written explanation of study given, permission sought to proceed
10-14 weeks’ gestation: Research midwife identifies eligible women by 
GP/midwife referral letters, USS, EPAU, ANC, Fetal Medicine 
DECLINED
Routine ANC.
BMI, ethnicity, age & 
pregnancy outcome 
recorded (if agreed)
14-15 weeks’ gestation: Research midwife 
makes telephone/ email contact to answer 
queries and obtain verbal consent
Baseline/Randomisation visit: 
15 +0 -18 +6 weeks’ gestation
Eligibility confirmed; written informed consent 
obtained. RANDOMISATION, demography, 
maternal history, maternal family history, 
current pregnancy health. Questionnaires:
dietary assessment (FFQ), binge eating, 
EQ-5D, IPAQ, EPDS. Anthropometry
Samples : blood & urine 
INTERVENTION
Appointment with Health
Trainer followed 
by 8 weekly 
sessions
CONTROL
Routine ANC
28 week visit:
27 +0 -28 +6 weeks’
Consent confirmed
Current pregnancy
health 
Questionnaires FFQ, 
EQ-5D, EPDS, binge 
eating & IPAQ.
Anthropometry.
Samples OGTT, Blood 
& urine.
Fetal USS 
36 week visit:
34 +0 -36 +0 weeks’
Consent confirmed, current pregnancy 
health. Questionnaires: FFQ , EQ-5D, 
binge eating, EPDS,IPAQ.
Anthropometry, Samples: blood & urine
Pregnancy, Delivery and Neonatal
Data:
Maternal late pregnancy, delivery data 
newborn data, neonatal anthropometry, 
cord blood sample, maternal postnatal 
and neonatal discharge information
Any time during 
study: 
FATHER 
consented for 
demography, 
DNA, 
anthropometry
6 month Follow-Up
Mother: Registration- contact 
details, eligibility, consent.
- demography, smoking,
general health, Anthropometry.
Samples, blood & urine 
Questionnaires: FFQ,EPDS, 
TFEQ-18, Binge eating, IPAQ, 
IBQR
Child- eligibility, hospital 
admissions, medications & 
supplements. Anthropometry. 
Questionnaires: BEBQ, feeding  
& growth, early 
care/education; sleep and 
activity
CONSENT NOT GIVEN
Routine ANC.
BMI, ethnicity, age & 
pregnancy outcome 
recorded (if agreed)
Session -week 6
Session -week 7
Session -week 8
Session -week 3
Session -week 1
Session -week 2
Session -week 4 
Session -week 5
Figure 1 (See legend on next page.)
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Figure 1 UPBEAT protocol summary. Abbreviations: ANC; Antenatal clinic, BEBQ; baby eating behaviour questionnaire, BMI; Body mass index,
DNA; Deoxyribonucleic acid, EPAU; Early pregnancy assessment unit, EPDS; Edinburgh postnatal depression score questionnaire. EQ-5D; EuroQuol
5 dimension quality of life questionnaire FFQ; Food frequency questionnaire, GP; General Practitioner, IBQ-R: Infant behaviour questionnaire re-
vised; IPAQ; International physical activity questionnaire; LGA; Large for gestational age OGTT; Oral glucose tolerance test, SGA; Small for gesta-
tional age, TFEQ-18; Three-factor eating questionnaire-R18, USS; Ultrasound scanning.
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All women in both groups attend for an oral glucose toler-
ance test (OGTT) at 27+0- 28+6 weeks’ gestation (fasting
for a minimum of 10 hours, 75 g glucose load). At this
visit weight and anthropometric measurements are taken,
health in current pregnancy noted, additional blood and
urine samples taken, dietary FFQ, EQ-5D, EPDS, IPAQ
and ‘binge eating’ questionnaires completed. Early preg-
nancy data including blood pressure, blood chemistry and
anomaly scan reports are entered from routine clinical
records.
34+0- 36+0 weeks’ appointment
Women in both arms of the study attend the research ap-
pointment at 34+0- 36+0 weeks’ gestation. Current health in
pregnancy is recorded, weight and anthropometric mea-
surements taken, blood and urine samples collected and
dietary FFQ, EQ-5D, EPDS, IPAQ and ‘binge eating’ ques-
tionnaires completed.
Unexpected adverse events are reported in accordance
with good clinical practice guidance.
Pregnancy outcome data
Following delivery, information is collected from mater-
nal medical records regarding health in late pregnancy,
labour onset, mode of delivery, blood loss, antenatal and
postnatal inpatient nights. Where possible a cord blood
sample is taken.
Neonatal and postnatal outcome data includes Apgar
scores, admission to special care baby unit and inpatient
nights. To address the influence of the intervention on fetal
growth and adiposity, neonatal anthropometry and length
measurements are undertaken within 72 hours of birth.
Six months postpartum
To determine whether the intervention has led to sus-
tained change in maternal dietary and physical activity be-
haviours, diet is assessed by FFQ and physical activity by
IPAQ. Maternal demographic data, health since pregnancy
and smoking history is obtained. Maternal anthropometric
measures are taken. EPDS, Three Factor Eating Question-
naire R18 (TEFQ-18) [39] and ‘binge eating’ question-
naires are completed. To address safety and the influence
of the intervention on the long term health of the child,
details regarding the child’s health from birth are obtained.
If cord blood was not taken, and if the parents provide
consent, a buccal cell sample is taken from the child’smouth for DNA extraction (Oragene™). To address the po-
tential influence of the intervention on infant adiposity at
6 months and obtain information on known determinants
of childhood obesity, infant length and other anthropo-
metric measures are taken. The mother provides informa-
tion for an infant feeding and growth questionnaire [40]
and a validated questionnaire addressing appetite (Baby
Eating and Behaviour Questionnaire (BEBQ) [41]. Infor-
mation on activity using questions from the Infant Behav-
iour Questionnaire -Revised (IBQ-R) [42] and sleep
patterns are obtained [43] and information on childcare
(kindergarten, other carers) collected.
Paternal data
At any point during the pregnancy or at the 6 month
postnatal appointment the father of the baby is asked to
consent to taking part in the study to provide informa-
tion which may influence the health of the child. A brief
medical history, blood pressure and pulse are checked,
anthropometric measurements taken and a blood sam-
ples collected for the provision for DNA. In the absence
of direct paternal measurement, women are asked to re-
call their partner’s height and weight and brief medical
and smoking history.
Study endpoints
Primary maternal outcome
GDM diagnosed by OGTT at 27+0 – 28+6 weeks’ ges-
tation according to the criteria recommended by IADPSG.
Diagnosis of GDM; fasting capillary glucose ≥ 5.1 mmol/L
and/or 1 hour glucose ≥10 mmol/L and/or 2 hour glucose
≥8.5 mmol/L [44].
Primary neonatal outcome
LGA delivery defined as adjusted birth weight >90th centile
[45] for gestational age adjusting for maternal height, cor-
rected maternal weight, ethnicity, parity, and sex of baby.
Secondary outcomes
Maternal - Pre-eclampsia, severe pre-eclampsia; mode of
delivery: caesarean section (elective, emergency, pre-labour,
in labour), vaginal delivery, operative vaginal delivery;
induction of labour; blood loss at delivery (>1000 ml;
>2000 ml); inpatient nights (antenatal, postnatal); GWG,
trimester specific GWG; fasting plasma glucose, fasting
plasma insulin, insulin resistance calculated by homeostatic
model assessment 2 (HOMA2-IR) [46] at 28 weeks’
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GDM antenatal service following OGTT; requirement for
insulin or metformin during pregnancy; fetal growth at
28 weeks. Health related quality of life as assessed by
EQ-5D. At 27+0- 28+6 and 34+0- 36+0 weeks’ gestation
and 6 months postpartum; mid-arm, neck, hip, thigh and
wrist circumference and skinfold thickness (subscapular,
triceps, biceps, supra-iliac); plasma fructosamine, triglyc-
erides, LDL, VLDL and HDL cholesterol, plasma insu-
lin, C-reactive protein, other relevant epigenetic and
metabolomic biomarkers, and urinary biomarkers; diet-
ary measures including glycemic load, saturated fat and
total sugar intake; dietary feeding patterns; physical
activity scores; measures of depression; maternal smoking.
At 6 months postpartum, postnatal weight retention,
existing maternal morbidity (diabetic status, hypertension,
thromboembolism, low mood [47]).
Neonatal; Gestational age at delivery, delivery at
<37 weeks’, delivery at <34 weeks’; birth weight, birth
weight >4,000 g, <2,500 g; birth weight >95th <10th and
<5th customised birth weight centile, distribution of birth
weight, neonatal death, days in special care baby unit,
total inpatient days, need for mechanical ventilation and
duration, discharge home on O2, suspected and confirmed
infection, evidence of intraventricular haemorrhage and
other complications, (pulmonary haemorrhage, necrotizing
enterocolitis), retinopathy of prematurity, hypoglycaemia.
Occipitofrontal head circumference, abdominal circum-
ference, mid-arm circumference, chest circumference,
crown-rump length and crown-heel length (neonatometer),
triceps and subscapular skin fold thicknesses and estimated
fat mass.
Key epigenetic and metabolomic biomarkers will be
investigated using cord blood or whole blood (maternal
and fetal) and their relation to specific outcomes.
Infant at 6 months; duration of breast feeding, choice
of formula milk, weaning history (introduction of foods
and frequency/timing of foods), a general measure of ap-
petite, and four specific scales: enjoyment of food, food
responsiveness, slowness in eating, and satiety respon-
siveness, anthropometric measurements (occipitofrontal
circumference, abdominal circumference, mid-arm cir-
cumference, chest circumference, crown-rump length
and crown-heel length by infantometer, subscapular and
triceps skin fold thicknesses and estimated fat mass; ac-
tivity (total number of 14 standard milestones reached)
and sleeping patterns (time spent sleeping; morning,
afternoon and night; health care resource use (hospital
admissions and medications); frequency of use of kinder-
garten/mother’s help.
Sub-group analysis
Women who are treated for GDM; differences in diagnos-
tic thresholds between centres will be accommodated byminimisation by centre. Other subgroups likely to be of
interest include demographic and socio-economic status
(assessed by Index Multiple Deprivation), ethnic groups,
BMI categories, groups of different parity and smokers.
Interaction tests will be used to determine whether
treatment is particularly effective in individual subgroups.
Performance of subgroup analysis will be dependent on
sufficient data. Because of the well known risk of false pos-
itives, both main effects and interaction tests will be per-
formed before considering results for subgroups.
Sample size
In the pilot RCT [32], 30% of women in the standard care
arm developed GDM according to the IADPSG criteria
[39]. 1546 women (including allowance for 20% drop out)
(773/arm) will be recruited to provide 80% power to de-
tect a 25% reduction in the incidence of GDM. Consider-
ing LGA deliveries, for a 30% relative risk reduction (RRR)
from an estimated 17.2% of LGA to 12.0% in the interven-
tion arm; 1546 women would give 80% power [48,49].
Analysis
To determine whether the trial participants are repre-
sentative of the general population, relevant parameters
available from electronic summary patient records will
be compared between eligible women agreeing and de-
clining to take part. Analyses will follow the intention-
to-treat principle.
Following CONSORT guidelines, risk ratios and risk
differences will be estimated by binary regression for Yes/
No outcomes. Where measurements are repeated over
time, results [mean (SD) or n (%)] will be presented separ-
ately at each time point. Randomised comparisons with
95% confidence intervals will be made using linear regres-
sion with robust standard errors, adjusting for the baseline
value where appropriate.
Multiple regression models will be used to address the
influence of maternal exposures on neonatal and infant
(6 months) body composition and the role of paternal
factors.
Discussion
This RCT will determine whether a complex interven-
tion addressing diet and physical activity will reduce the
incidence of GDM and LGA infants in a population of
obese pregnant women receiving antenatal care in the
UK. The study will inform guidelines on the manage-
ment of obesity in pregnancy, and if successful, is de-
signed to be rapidly transferrable to clinical practice.
Determination of infant anthropometry at 6 months of
age will assess whether the intervention in pregnancy
can influence body composition of the infant. Further
studies on childhood body composition at 3 years of age
will also be undertaken.
Briley et al. BMC Pregnancy and Childbirth 2014, 14:74 Page 8 of 9
http://www.biomedcentral.com/1471-2393/14/74Abbreviations
BMI: Body mass index; FFQ: Food frequency questionnaire; EPDS: Edinburgh
Postnatal Depression Scale; EQ-5D: EuroQuol-5D; GDM: Gestational diabetes
mellitus; GI: Glycemic index; GL: Glycemic load; GWG: Gestational weight
gain; HOMA2-IR: Homeostatic Model Assessment-Insulin resistance;
IADPSG: International Association of Diabetes Pregnancy Study Group;
IPAQ: International Physical Activity Questionnaire; LGA: large for gestational
age; O2: Oxygen; OGTT: Oral glucose tolerance test; PE: Pre-eclampsia;
RCT: Randomised controlled trial; RRR: Relative risk reduction; SGA: Small for
gestational age; SMART (goals): Specific, Measurable, Achievable, Relevant
and Time-Specific.
Competing interests
None of the authors disclosed any financial or non-financial competing
interests.
Authors’ contributions
LP, ALB and KMG contributed to all aspects design of the study and LP and
ALB had overall responsibility for the study. LP, ALB, NP drafting of the
manuscript; BH, TS and SB(Barr) contributed to development of the dietary
elements of the intervention; RB, TIK and SCR contributed to the
development of the physical activity elements of the intervention; HC and
JW contributed to development of the behavioural elements of intervention,
SMN and NS contributed to assessment of maternal glucose homeostasis
and biochemical analyses; EO-N contributed to the development of the final
protocol; JS and SB(Badger) through process evaluation of the pilot trial con-
tributed to development of the final protocol; PTS developed the data ana-
lysis protocol. All authors were involved in drafting of the manuscript and
gave approval for the final version of the manuscript.
Authors’ information
LP is Professor of Maternal and Fetal Health, TS is Professor of Nutritional
Science, SB(Badger) a Research Associate and SB(Barr) a Research Dietician at
King’s College London; RB is a Senior Lecturer in Public Health Medicine, and
SCR Professor of Fetal Medicine at Newcastle University; KMG is Professor of
Epidemiology & Human Development and Director Centre for the
Developmental Origins of Health and Disease at Southampton University;
SMN is Professor of Reproductive and Maternal Medicine, and NS Professor
of Metabolic Medicine at Glasgow University; EO-N is a Consultant Obstetri-
cian and ALB a Consultant Midwife at Guy’s and St. Thomas’ NHS Foundation
Trust, London; PTS is a Senior Lecturer in Medical Statistics at King’s College
London and JW is Professor in Clinical Psychology and Director of the Health
Behaviour Unit at University College London. TIK, HC and NP are research
fellows.
Acknowledgements
This paper presents independent research funded by the National Institute
of Health Research (NIHR) under the Programme Grants for Applied Research
programme (RP-PG-0407-10452). The views expressed are those of the
authors and not necessarily those of the National Health Service, the NIHR or
the Department of Health. The study is also part funded Guys and St.
Thomas’ Charity and the Chief Scientist Office, Scottish Government Health
Directorates, Edinburgh, UK. LP, PTS and ALB is part funded by Tommy’s
Charity. KG is supported by the National Institute for Health Research
through the Southampton NIHR Nutrition, Diet & Lifestyle Biomedical
Research Unit.
Author details
1Division of Women’s Health, Women’s Health Academic Centre, King’s
College London and King’s Health Partners, 10th floor, North Wing, St.
Thomas’ Hospital, London SE1 7EH, UK. 2Division of Diabetes and Nutritional
Sciences, King’s College London and King’s Health Partners, London, UK.
3Institute of Health & Society, Newcastle University, Newcastle, UK.
4Epidemiology and Public Health, University College London, London, UK.
5MRC LifeCourse Epidemiology Unit, University of Southampton,
Southampton, UK. 6NIHR Biomedical Research Unit in Nutrition, Diet and
Lifestyle, University of Southampton Hospital NHS Foundation Trust,
Southampton, UK. 7Centre for Population and Health Sciences, School of
Medicine, University of Glasgow, Glasgow, UK. 8Institute of Cellular Medicine,
Newcastle University, Newcastle, UK.Received: 28 January 2014 Accepted: 10 February 2014
Published: 18 February 2014References
1. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML,
Gortmaker SL: The global obesity pandemic: shaped by global drivers
and local environments. Lancet 2011, 378:804–814.
2. World Health Organization: WHO Global Database 2008. 2011. N311,
http://www.who.int/mediacentre/factsheets/fs311/en/. Date accessed
09.01.2014.
3. Sutton R: Adult anthropometric measures, overweight and obesity. Health
Surv Engl 2012, 1:1–37.
4. Centre for Maternal and Child Enquiries: Saving Mothers’ lives: reviewing
maternal deaths to make motherhood safer: 2006–2008. BJOG 2011,
118:1–203.
5. Heslehurst N, Simpson H, Ells LJ, Rankin J, Wilkinson J, Lang R, Brown TJ,
Summerbell CD: The impact of maternal BMI status on pregnancy outcomes
with immediate short-term obstetric resource implications: a meta-analysis.
Obes Rev 2008, 9:635–683.
6. Tsoi E, Shaikh H, Robinson S, Teoh TG: Obesity in pregnancy: a major
healthcare issue. Postgrad Med J 2010, 86:617–623.
7. Nelson SM, Matthews P, Poston L: Maternal metabolism and obesity:
modifiable determinants of pregnancy outcome. Hum Reprod Update
2010, 16:255–275.
8. Poston L, Harthoorn LF, van der Beek EM: Obesity in pregnancy: implications
for the mother and lifelong health of the child. A consensus statement.
Pediatr Res 2011, 69:175–180.
9. Institue of Medicine and National Research Council: Weight Gain During
Pregnancy: Reexamining the Guidelines. Washington DC: The National
Academies Press; 2009.
10. National Institute for Health and Clinical Excellence: Dietary interventions
and physical activity interventions for weight management before,
during and after pregnancy. Public Health Guid 2010, 27. http://www.nice.
org.uk/nicemedia/live/13056/49926/49926.pdf. Date accessed 05.12.2013.
11. Dodd JM, Grivell RM, Crowther CA, Robinson JS: Antenatal interventions
for overweight or obese pregnant women: a systematic review of
randomised trials. BJOG 2010, 117:1316–1326.
12. Thangaratinam S, Rogozińska E, Jolly K, Glinkowski S, Roseboom T,
Tomlinson JW, Kunz R, Mol BW, Coomarasamy A, Khan KS: Effects of
interventions in pregnancy on maternal weight and obstetric outcomes:
meta-analysis of randomised evidence. BMJ 2012, 344:e2008.
13. Nohr EA, Vaeth M, Baker JL, Sørensen TI, Olsen J, Rasmussen KM: Combined
associations of prepregnancy body mass index and gestational weight
gain with the outcome of pregnancy. Am J Clin Nutr 2008, 87:1750–1759.
14. Viswanathan MS-RA, Moos MK, Deierlein A, Mumford S, Knaack J, Thieda P,
Lux LJ, Lohr KN: Outcomes of maternal weight gain. In Evidence reports/
technology assessments, No 168. United States: Agency for Healthcare Re-
search and Quality; 2008.
15. Lowe LP, Metzger BE, Dyer AR, Lowe J, McCance DR, Lappin TRJ, Trimble ER,
Coustan DR, Hadden DR, Hod M, et al: Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) study: associations of maternal a1c and
glucose with pregnancy outcomes. Diabetes Care 2012, 35:574–580.
16. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarinder U, Coustan DR,
Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers
MS, Sacks SA: Hyperglycemia and adverse pregnancy outcomes. N Engl J
Med 2008, 358:1991–2002.
17. Harmon KA, Gerard L, Jensen DR, Kealey EH, Hernandez TL, Reece MS,
Barbour LA, Bessesen DH: Continuous glucose profiles in obese and
normal-weight pregnant women on a controlled diet: metabolic
determinants of fetal growth. Diabetes Care 2011, 34:2198–2204.
18. Vrijkotte TGM, Algera SJ, Brouwer IA, van Eijsden M, Twickler MB: Maternal
triglyceride levels during early pregnancy are associated with birth weight
and postnatal growth. J Pediatr 2011, 159:736–742.
19. Parretti E, Lapolla A, Dalfrà M, Pacini G, Mari A, Cioni R, Marzari C, Scarselli G,
Mello G: Preeclampsia in lean normotensive normotolerant pregnant
women can be predicted by simple insulin sensitivity indexes.
Hypertension 2006, 47:449–453.
20. Zhang C, Ning Y: Effect of dietary and lifestyle factors on the risk of
gestational diabetes: review of epidemiologic evidence. Am J Clin Nutr
2011, 94:1975S–1979S.
Briley et al. BMC Pregnancy and Childbirth 2014, 14:74 Page 9 of 9
http://www.biomedcentral.com/1471-2393/14/7421. Wolff S, Legarth J, Vangsgaard K, Toubro S, Astrup A: A randomized trial of
the effects of dietary counseling on gestational weight gain and glucose
metabolism in obese pregnant women. Int J Obes 2008, 32:495–501.
22. Quinlivan JA, Lam LT, Fisher J: A randomised trial of a four-step multidis-
ciplinary approach to the antenatal care of obese pregnant women. Aust
N Z J Obstet Gynaecol 2011, 51:141–146.
23. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS: Effect
of treatment of gestational diabetes mellitus on pregnancy outcomes.
N Engl J Med 2005, 352:2477–2486.
24. Landon MB: Is there a benefit to the treatment of mild gestational
diabetes mellitus? Am J Obstet Gynecol 2010, 202:649–653.
25. Ruchat SM, Mottola MF: The important role of physical activity in the
prevention and management of gestational diabetes mellitus. Diabetes
Metab Res Rev 2013, 29:334–346.
26. Louie JCYBJ, Makovic TP, Ross GP, Moses RG: Glycemic index and
pregnancy: a systematic literature review. J Nutrit Metab 2010, 2010:1–8.
27. Oteng-Ntim E, Varma R, Croker H, Poston L, Doyle P: Lifestyle interventions
for overweight and obese pregnant women to improve pregnancy
outcome: systematic review and meta-analysis. BMC Med 2012, 10:47.
28. Gardner B, Wardle J, Poston L, Croker H: Changing diet and physical
activity to reduce gestational weight gain: a meta-analysis. Obes Rev
2011, 12:e602–e620.
29. Poston LCL: How should women be advised on weight management in
pregnancy? BMJ 2012, 344:e2774.
30. Carver CS, Scheier MF: Origins and functions of positive and negative
affect: a control-process view. Psychol Rev 1990, 97:19–35.
31. Bandura A: Health promotion by social cognitive means. Health Educ
Behav 2004, 31:143–164.
32. Poston L, Briley A, Barr S, Bell R, Croker H, Coxon K, Essex H, Hunt C, Hayes
L, Howard L, et al: Developing a complex intervention for diet and
activity behaviour change in obese pregnant women (the UPBEAT trial);
assessment of behavioural change and process evaluation in a pilot
randomised controlled trial. BMC Pregnancy Childbirth 2013, 13:148.
33. Royal college of obstetricians and gynaecologists: exercise in pregnancy.
2006, RCOG statement 4. http://www.rcog.org.uk/womens-health/clinical-
guidance/exercise-pregnancy. Date accessed 12.12.2013.
34. Bingham SA, Gill C, Welch A, Cassidy A, Runswick SA, Oakes S, Lubin R,
Thurnham DI, Key TJ, Roe L, et al: Validation of dietary assessment
methods in the UK arm of EPIC using weighed records, and 24-hour
urinary nitrogen and potassium and serum vitamin C and carotenoids as
biomarkers. Int J Epidemiol 1997, 26:S137.
35. EuroQol: EuroQol- A New facility for the measurement of health-related
quality of life. Health Policy 1990, 19:199–208.
36. Cox JLHJ, Sagovsky R: Detection of postnatal depression. Development of
the 10-item edinburgh postnatal depression scale. Br J Psychiatry 1987,
150:782–786.
37. Ekelund USH, Brage S, Becker W, Jakes R, Hennings M, Wareham NJ:
Crierion-related validity of the last 7 Day, short form of the international
physical activity questionnaire in swedish adults. Public Health Nutr 2006,
9:258–265.
38. Stice E, Fisher M, Martinez E: Eating disorder diagnostic scales: additional
evidence of reliability and validity. Psychol Assess 2004, 16:60–71.
39. Stunkard AJ, Messick S: The three-factor eating questionnaire to measure
dietary restraint, disinhibition and hunger. J Psychosom Res 1985,
29:71–83.
40. Robinson S, Marriott L, Poole J, Crozier S, Borland S, Lawrence W, Law C,
Godfrey K, Cooper C, Inskip H: Dietary patterns in infancy: the importance
of maternal and family influences on feeding practice. Br J Nutr 2007,
98:1029–1037.
41. Llewellyn CH vJC, Johnson L, Carnell S, Wardle J: Development and factor
structure of the baby eating behaviour questionnaire in the gemini birth
cohort. Appetite 2011, 57:388–396.
42. Gartstein MARM: Studying infant temperament via the revised infant
behaviour questionnaire. Infant Behav Dev 2003, 26:64–86.
43. Sadeh A: A brief screening questionnaire for infant sleep problems:
validation and findings for an internet sample. Pediatrics 2004,
113:e570–e577.
44. International Association of Diabetes Pregnancy Study Groups Consensus
Panel: International association of diabetes and pregnancy study groups
recommendations on the diagnosis and classification of hyperglycemia
in pregnancy. Diabetes Care 2010, 33:676–682.45. Gardosi J, Francis A: Software program for the calculation of customised
birth weight percentiles. 2002-2007. [Accessed January 2010].
www.gestation.net.
46. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling.
Diabetes Care 2004, 27:1487–1495.
47. Gibson JM-MK, Shakespeare J, Price J, Gray R: A systematic review of
studies validating the edinburgh postnatal depression scale in antepartum
and postpartum women. Acta Psychiatr Scand 2009, 119:350–364.
48. Sebire N, Jolly M, Harris J, Wadsworth J, Joffe M, Beard R: Maternal obesity
and pregnancy outcome: a study of 287, 213 pregnancies in london.
Int J Obes (Lond) 2001, 25:1175–1182.
49. Ehrenberg H, Durnwald C, Catalano P, Mercer B: The influence of obesity
and diabetes on the risk of cesarean delivery. Am J Obstet Gynaecol 2004,
191:969–974.
doi:10.1186/1471-2393-14-74
Cite this article as: Briley et al.: A complex intervention to improve
pregnancy outcome in obese women; the UPBEAT randomised
controlled trial. BMC Pregnancy and Childbirth 2014 14:74.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
